DOI: 10.1055/s-00000088

TumorDiagnostik & Therapie

References

Des Guetz G. et al.
Anti PD-1 (nivolumab, pembrolizumab) or anti PD-L1 (atezolizumab) versus docetaxel for previously treated patients with advanced NSCLC: A meta-analysis.

J Clin Oncol; 2016
34. (suppl; abstr e20555)

Download Bibliographical Data

Access: